We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In.
HUTCHMED (China) Limited (NASDAQ:HCM) is one of the most undervalued pharma stocks
TheFly reported on May 28 that Morgan Stanley upgraded HCM to Equal Weight from Underweight and set a new price target of $13.60, slightly below the prior $13.75 level. The firm noted that China biotech valuations have reset to more attractive entry levels, improving the sector’s risk-reward profile. It also pointed to FY26 guidance that continues to suggest solid growth in innovator revenue, alongside ongoing strength in outbound licensing activity.
On May 21, HUTCHMED (China) Limited (NASDAQ:HCM) and Innovent Biologics announced that China’s National Medical Products Administration (NMPA) approved their New Drug Application for the combination therapy of Elunate and Tyvyt. The approval covers the treatment of patients with locally advanced or metastatic renal cell carcinoma who have previously been treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors and have not received PD-1 or PD-L1 inhibitor therapy in the first-line setting. This regulatory decision expands the clinical use of the combination regimen in a more defined patient population with prior treatment exposure.